Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Ongoing treatment with Dmab did not blunt the anabolic response of Romo, indicating sustained modeling-based bone formation activity. Adding Romo in patients failing Dmab might be a valuable option.
Authors
- Anna Lisa Piccinelli (ORCID: https://orcid.org/0000-0001-6102-2762)
- Camilla Benini (ORCID: https://orcid.org/0000-0002-8082-5023)
- Ombretta Viapiana (ORCID: https://orcid.org/0000-0003-1917-5655)
- Francesco Pollastri (ORCID: https://orcid.org/0009-0006-1691-2196)
- Maurizio Rossini (ORCID: https://orcid.org/0000-0001-9692-2293)
- Emma Pasetto
- Davide Gatti (ORCID: https://orcid.org/0000-0002-7471-3076)
- Angelo Fassio (ORCID: https://orcid.org/0000-0001-9187-232X)
- Carmela Dartizio
- Giovanni Adami (ORCID: https://orcid.org/0000-0002-8915-0755)
- Filippo Montanari
Institutions
- University of Verona (IT)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1002/art.70002
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00